Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL165885 | 0.96 | ALDH1A1 (0.49) | ALDH1A1MAPTCES2CES1GAA | |
| SCHEMBL534242 | 0.94 | CES2 (0.52) | ALDH1A1MAPTCES2CES1GAA | |
| SCHEMBL7636018 | 0.94 | CES2 (0.52) | ALDH1A1MAPTCES2CES1GAA | |
| SCHEMBL7638404 | 0.94 | CES2 (0.52) | ALDH1A1MAPTCES2CES1GAA | |
| SCHEMBL6642281 | 0.91 | MAPT (0.47) | ALDH1A1MAPTGAARAB9ANPSR1 | |
| SCHEMBL27967581 | 0.85 | TRPM8 (0.38) | ALDH1A1MAPTGAASMN1; SMN2RAB9A | |
| SCHEMBL14934954 | 0.84 | ALDH1A1 (0.41) | ALDH1A1MAPTCES2CES1GAA | |
| SCHEMBL14993986 | 0.83 | MAPT (0.42) | ALDH1A1MAPTGAARAB9AMEN1 | |
| SCHEMBL3940169 | 0.82 | TSHR (0.43) | ALDH1A1MAPTGAARAB9AKMT2A | |
| SCHEMBL4631018 | 0.82 | GABRP (0.43) | ALDH1A1MAPTGAASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2643000-A2 | THERAPEUTIC PIPERAZINES | Dart Neuroscience (Cayman) Ltd (KY) | 2013-10-02 | — | — | EP | claimed |
| WO-2012040258-A2 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. (US) | 2012-03-29 | — | — | WO | claimed |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | claimed |
| EP-4720072-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260078133-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2026-03-19 | — | — | US | disclosed |
| WO-2024249299-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-9624200-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-04-18 | — | — | US | disclosed |
| US-20160319312-A1 | SYNTHESIS METHOD FOR L-CYCLIC ALKYL AMINO ACID AND PHARMACEUTICAL COMPOSITION HAVING THEREOF | TIANJIN ASYMCHEM PHARMACEUTICAL CO., LTD. (CN) | 2016-11-03 | — | — | US | disclosed |
| US-20160319312-A1 | SYNTHESIS METHOD FOR L-CYCLIC ALKYL AMINO ACID AND PHARMACEUTICAL COMPOSITION HAVING THEREOF | TIANJIN ASYMCHEM PHARMACEUTICAL CO., LTD. (CN) | 2016-11-03 | — | — | US | disclosed |
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. | 2015-03-26 | — | — | US | disclosed |
| US-8927546-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-01-06 | — | — | US | disclosed |
| CN-103361388-A | L-cyclic alkylamino acid synthesis method and medicinal composition containing L-cyclic alkylamino acid | ASYMCHEM LAB TIANJIN CO LTD | 2013-10-23 | — | — | CN | disclosed |
| EP-2643000-A2 | THERAPEUTIC PIPERAZINES | Dart Neuroscience (Cayman) Ltd (KY) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012040258-A2 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | disclosed |
| US-6348617-B1 | REACTING PYRUVIC ACID COMPOUND IN WATER WITH AMMONIUM OR ALKALI METAL BISULFITE TO GIVE AQUEOUS SOLUTION OF BISULFITE ADDUCT, ISOLATING BY PHASE SEPARATION, OPTIONALLY USING HYDROPHOBIC SOLVENT, CONTACTING WITH ACID TO DECOMPOSE ADDUCT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-0937703-A1 | METHOD FOR PURIFYING PYRUVIC ACID COMPOUNDS | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1999-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | ALDH1A1 1228/4885MAPT 1996/4885CES2 584/4885 |
| US-20260078133-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 3635/4885MAPT 4345/4885CES2 3894/4885 |
| US-20160319312-A1 | SYNTHESIS METHOD FOR L-CYCLIC ALKYL AMINO ACID AND PHARMACEUTICAL COMPOSITION HAVING THEREOF | ADH1B, BCAT2, BCAT1 | ALDH1A1 158/4885MAPT 3553/4885CES2 1614/4885 |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | ALDH1A1 1228/4885MAPT 1996/4885CES2 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.